X4 Pharmaceuticals Inc
$ 3.70
2.21%
16 Jan - close price
- Market Cap 323,516,000 USD
- Current Price $ 3.70
- High / Low $ 3.75 / 3.58
- Stock P/E N/A
- Book Value 2.45
- EPS -8.92
- Next Earning Report -
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA -0.34 %
- ROE -1.57 %
- 52 Week High 24.42
- 52 Week Low 1.35
About
X4 Pharmaceuticals Inc. is a Boston-based clinical-stage biopharmaceutical company dedicated to developing breakthrough therapies for rare and serious diseases, particularly those related to back disorders. Leveraging its proprietary technology, X4 is advancing a promising pipeline of investigational therapies designed to meet critical unmet medical needs and improve patient outcomes. With a strong commitment to innovative clinical development and a clear focus on underserved patient populations, X4 is strategically positioned to make a significant impact in the biopharmaceutical sector and potentially establish itself as a leader in therapeutic solutions.
Analyst Target Price
$8.00
Quarterly Earnings
| Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | Dec 2022 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2025-11-05 | 2025-08-08 | 2025-05-05 | 2025-03-19 | 2024-11-13 | 2024-08-08 | 2024-05-07 | 2024-03-21 | 2023-11-09 | 2023-08-10 | 2023-05-04 | 2023-03-21 |
| Reported EPS | -0.69 | -3.47 | 0.04 | -0.2 | -0.18 | -0.07 | -0.26 | -0.1 | -0.01 | -0.33 | -0.16 | -0.29 |
| Estimated EPS | -0.125 | -0.0883 | -3.75 | -0.1575 | -0.17 | 0.01 | -0.16 | -0.15 | -0.15 | -0.16 | -0.22 | -0.24 |
| Surprise | -0.565 | -3.3817 | 3.79 | -0.0425 | -0.01 | -0.08 | -0.1 | 0.05 | 0.14 | -0.17 | 0.06 | -0.05 |
| Surprise Percentage | -452% | -3829.7848% | 101.0667% | -26.9841% | -5.8824% | -800% | -62.5% | 33.3333% | 93.3333% | -106.25% | 27.2727% | -20.8333% |
Next Quarterly Earnings
| Reported Date |
| Fiscal Date Ending |
| Estimated EPS |
| Currency |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: XFOR
2026-01-18 17:05:00
Individual investors hold the largest share of X4 Pharmaceuticals (NASDAQ:XFOR) with 52% ownership, giving them significant influence over company decisions. Institutions account for 31% of stockholders, while insiders own less than 1% of the shares. Hedge funds collectively own 10%, with Empery Asset Management, LP being the largest among them.
2026-01-18 13:07:04
X4 Pharmaceuticals (NASDAQ: XFOR) is predominantly owned by individual investors, who hold a 52% stake, followed by institutions at 31%. Hedge funds control 10% of the shares, with Empery Asset Management, FMR LLC, and Perceptive Advisors LLC being among the largest institutional shareholders. Insiders own less than 1% of the company, and the article notes some recent insider buying.
2025-12-31 15:08:28
Short interest in X4 Pharmaceuticals (NASDAQ:XFOR) increased by 27.1% to over 3.1 million shares as of December 15th, representing 3.7% of the stock. Despite a "Hold" consensus among analysts with an average price target of $34.50, insiders and institutions have been increasing their holdings. Chairman Adam R. Craig notably bought 86,206 shares, boosting his stake by nearly 30%.
2025-12-25 05:09:12
X4 Pharmaceuticals (XFOR) is showing technical bullish signals, including a "golden cross" where its 50-day simple moving average crossed above its 200-day simple moving average. This, combined with positive movements in Zacks Consensus Estimates and a #3 (Hold) Zacks Rank, suggests potential for future gains. Investors are encouraged to monitor XFOR for further upward movement.
2025-12-24 17:09:13
X4 Pharmaceuticals, Inc. (XFOR) currently holds a price-to-sales (P/S) ratio of 10.6x, comparable to the Biotech industry median, despite recent significant revenue growth. However, future revenue growth projections of 47% per year are considerably lower than the industry's anticipated 121% growth. This discrepancy suggests that the current P/S ratio may be unsustainable, indicating elevated risks for existing shareholders and potential investors.
2025-12-24 17:08:36
X4 Pharmaceuticals' P/S ratio of 10.6x is near the biotech industry median, but its projected revenue growth of 47% per year falls significantly short of the industry's 121% forecast. This discrepancy suggests the stock may be overvalued, as investors appear to be overlooking limited growth expectations. The article highlights that maintaining current prices will be difficult with such subdued revenue growth.
